Seeing Is Believing
Currently out of the existing stock ratings of Colin Bristow, 61 are a BUY (57.01%), 46 are a HOLD (42.99%).
Analyst Colin Bristow works at UBS with a stock forecast success ratio of 52.78% fulfilled within 191.95 days on average.
Colin Bristow’s has documented 214 price targets and ratings displayed on 21 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on AMGN, Amgen at 17-Apr-2024.
Analyst best performing recommendations are on IMVT (IMMUNOVANT ).
The best stock recommendation documented was for IMVT (IMMUNOVANT ) at 9/26/2022. The price target of $5 was fulfilled within 3 days with a profit of $0.48 (10.62%) receiving and performance score of 35.4.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
205
$22.5 (12.33%)
2 years 11 months 20 days ago
3/5 (60%)
$35.09 (20.65%)
938
Hold
173
$-9.5 (-5.21%)
156
2 years 11 months 22 days ago
14/24 (58.33%)
$2.73 (1.60%)
682
Hold
190
$7.5 (4.11%)
194
3 years 2 months 21 days ago
9/11 (81.82%)
$34.41 (22.12%)
350
Hold
166
$-16.5 (-9.04%)
175
3 years 2 months 21 days ago
23/23 (100%)
$10.41 (6.69%)
828
Buy
155
3 years 3 months 18 days ago
7/7 (100%)
$36.79 (31.12%)
395
Which stock is Colin Bristow is most bullish on?
Which stock is Colin Bristow is most reserved on?
What Year was the first public recommendation made by Colin Bristow?